Vitamin D Level in Recurrent PV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-01

Study Completion Date

2022-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Serum Samples will be taken from patients with recurrent Pityriasis Versicolor for the evaluation of vitamin D level.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin D Level and Risk of Infections in Cirrhotic Patients

NCT03391245

Vitamin D Deficiency Infection Liver Cirrhosis

UNKNOWN

Vitamin D Estimation With Giardia Lamblia Infections

NCT04778280

Giardia Lamblia Infection

UNKNOWN

Serum 25(OH) Vitamin D and Total Serum Immunoglobulin E Levels in Patients With Pityriasis Alba

NCT03443765

Pityriasis Alba

ACTIVE_NOT_RECRUITING

A Study of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients

NCT01548716

Vitamin D Deficiency End Stage Renal Disease

COMPLETED

Vitamin D Level and Its Relation to Pre-eclampsia and Eclampsia

NCT03882099

Vitamin D Deficiency Pre-Eclampsia Eclampsia, Antepartum

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Pityriasis Versicolor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

recurrent pityriasis versicolor

Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)

Intervention Type DIAGNOSTIC_TEST

The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).

Controls

Healthy age and sex matched

Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)

Intervention Type DIAGNOSTIC_TEST

The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)

The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.
* Patients of both genders.
* Age ≥18 years old.

Exclusion Criteria

* \- Patients with other cutaneous diseases.
* Patient's having dandruff (scaly scalp) even if not symptomatizing.
* Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.
* Patients with autoimmune diseases.
* Patients with immunodeficiency diseases.
* Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No